Idiopathic Pulmonary FibrosisPhase 2NCT07284459
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
A Phase 2 study testing PIPE-791 Dose A and PIPE-791 Dose B in people with Idiopathic Pulmonary Fibrosis, run by Contineum Therapeutics at 108 sites in 19 countries.
Trial summary
This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with or without background treatment. Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Idiopathic Pulmonary Fibrosis
- What is being tested?
- PIPE-791 Dose A and PIPE-791 Dose B
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 324 participants
- Where
- 108 sitesin 19 countries
- Study dates
- 8 Jan 2026to Jun 2028
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female ≥ 40 years of age at the time of Randomization.
- A diagnosis of IPF within 7 years prior to Screening, based on the 2022 ATS/ERS/JRS/ALAT practice guideline as confirmed by the Investigator, and a centrally read screening HRCT consistent with usual interstitial pneumonia (UIP) or probable UIP.
- Percent predicted (pp) FVC ≥ 40% on Screening spirometry.
- Participants may enter the study whether or not they are receiving background nintedanib or pirfenidone therapy approved for the treatment of IPF, but not both concurrently.
Who cannot join
- Those with a history of interstitial lung disease (ILD) other than IPF are not eligible.
- Those with pulmonary arterial hypertension (PAH) requiring multi-drug therapy are not eligible.
- Those who have experienced an IPF exacerbation within 6 weeks of Screening, or during Screening, are not eligible.
- Those with an estimated glomerular filtration rate (eGFR) ≤ 30 ml/min/1.73 m2 (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) (Inker 2021) or who have Child-Pugh Class B or C hepatic impairment are not eligible.
- Female participants must not be of childbearing potential.
- Additional inclusion and exclusion criteria apply.
Trial locations and contacts
108 sites in 19 countries. Contact the study team or a site near you to ask about taking part.
108 sites in 19 countries
Argentina15 sites, 15 recruiting
- Recruiting
CINME S.A. - Centro de Investigaciones Metabólicas - Viamonte 2213/2215
Buenos Aires, Buenos Aires F.D., C1056ABI
- Recruiting
STAT Research S.A.
Buenos Aires, C1023AAB
- Recruiting
Consultorios Médicos Organización del Buen Ayre SRL
Buenos Aires, C1425FVH
- Recruiting
Centro Médico Dra de Salvo - Fundacion Respirar - PPDS
Buenos Aires, C1426ABP
- Recruiting
Instituto de Medicina Respiratoria - IMER
Córdoba, X5003DCE
- Recruiting
Instituto Ave Pulmo
Mar del Plata, Buenos Aires, B7602DCK
- Recruiting
Centro Respiratorio Quilmes
Quilmes, Buenos Aires, B1878FNR
- Recruiting
Instituto de Especialidades de la Salud Rosario - Clínica del Tórax
Rosario, Santa Fe Province, S2000DBS
- Recruiting
Instituto Médico de la Fundación Estudios Clínicos
Rosario, Santa Fe Province, S2000DEJ
- Recruiting
Centro de Diagnóstico Y Rehabilitación - Santa Fe - San Luis
San Luis, Santa Fe Province, S3000GBL
- Recruiting
Centro de Investigaciones Médicas Tucumán - PPDS
San Miguel de Tucumán, Tucumán Province, T4000AXL
- Recruiting
CIMER-Centro Integral de Medicina Respiratoria
San Miguel de Tucumán, Tucumán Province, T4000CBC
- Recruiting
IPR-Investigaciones en Patologías Respiratorias
San Miguel de Tucumán, Tucumán Province, T4000IAP
- Recruiting
Centro Modelo de Cardiología-Laprida 554
San Miguel de Tucumán, Tucumán Province, T4000IFL
- Recruiting
IbaMedica
Santa Fe, S3000ASF
Israel11 sites, 11 recruiting
- Recruiting
Assuta Ashdod University Medical Center
Ashdod, Southern District, 7747629
- Recruiting
The Barzilai University Medical Center
Ashkelon, Southern District, 7830604
- Recruiting
Shamir Medical Center
Be’er Ya‘aqov, Central District, 7033001
- Recruiting
Hillel Yaffe Medical Center
Hadera, Haifa District, 3820302
- Recruiting
Hadassah Medical Center- Ein Kerem - PPDS
Jerusalem, Jerusalem, 9112001
- Recruiting
Shaare Zedek Medical Center
Jerusalem, Yerushala, 9103102
- Recruiting
Meir Medical Center
Kafr Saba, Central District, 4428164
- Recruiting
Rabin Medical Center - PPDS
Petah Tikva, Central District, 4941492
- Recruiting
The Chaim Sheba Medical Center - PPDS
Ramat Gan, Central District, 5262100
- Recruiting
Kaplan Medical Center
Rehovot, Central District, 7661041
- Recruiting
Tel Aviv Sourasky Medical Center Ichilov - PPDS
Tel Aviv, 6423906
Australia9 sites, 9 recruiting
- Recruiting
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050
- Recruiting
Lung Research Qld
Chermside, Queensland, 4032
- Recruiting
The Prince Charles Hospital
Chermside, Queensland, 4032
- Recruiting
Greenslopes Private Hospital
Greenslopes, Queensland, 4120
- Recruiting
Austin Health
Heidelberg, Victoria, 3084
- Recruiting
The Alfred Hospital
Melbourne, Victoria, 3004
- Recruiting
Institute for Respiratory Health
Midland, Western Australia, 6056
- Recruiting
TrialsWest Pty Ltd
Spearwood, Western Australia, 6163
- Recruiting
Westmead Hospital
Westmead, New South Wales, 2145
South Korea9 sites, 9 recruiting
- Recruiting
The Catholic University of Korea, Bucheon St. Mary's Hospital
Bucheon-si, Gyeonggi-do, 14647
- Recruiting
Gachon University Gil Medical Center
Incheon, 21565
- Recruiting
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620
- Recruiting
The Catholic University of Korea - Eunpyeong St. Mary's Hospital
Seoul, Eunpyeong District, 03312
- Recruiting
Severance Hospital Yonsei University Health System
Seoul, Seodaemun, 03722
- Recruiting
Samsung Medical Center
Seoul, Seoul, 06351
- Recruiting
Soon Chun Hyang University Hospital
Seoul, Yongsan-gu, 04401
- Recruiting
Korea University Anam Hospital
Seoul, 2841
- Recruiting
Asan Medical Center
Songpa-dong, Seoul, 05505
Canada7 sites, 7 recruiting
- Recruiting
Dynamic Drug Advancement Ltd.
Ajax, Ontario, L1S 2J5
- Recruiting
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2X 0A9
- Recruiting
Institut Universitaire de Cardiologie et de Pneumologie de Quebec - Université Laval
Québec, Quebec, G1V 4G5
- Recruiting
Toronto General Hospital
Toronto, Ontario, M5G 2C4
- Recruiting
Centre d'investigation Clinique Mauricie
Trois-Rivières, Quebec City, G8T 7A1
- Recruiting
Vancouver General Hospital
Vancouver, British Columbia, V5Z 1M9
- Recruiting
Dr. Anil Dhar Medicine Professional Corporation
Windsor, Ontario, N8X 5A6
Greece7 sites, 7 recruiting
- Recruiting
University General Hospital of Alexandroupolis
Alexandroupoli, Evros, 681 00
- Recruiting
Thoracic General Hospital of Athens I SOTIRIA
Athens, Anatoliki Attiki, 115 27
- Recruiting
University General Hospital - General Hospital of West Attica H Agia Varvara
Chaïdári, Anatoliki Attiki, 124 62
- Recruiting
General Hospital of Thessaloniki ''G. Papanikolaou''
Exochi, Thessaloniki, 570 10
- Recruiting
PAGNI-University General Hospital of Heraklion
Heraklion, Irakleio, 715 00
- Recruiting
University General Hospital of Ioannina
Ioannina, Ioannina, 455 00
- Recruiting
University General Hospital of Patras
Pátrai, Achaïa, 265 04
United Kingdom7 sites, 7 recruiting
- Recruiting
Birmingham Heartlands Hospital
Birmingham, B3 3HX
- Recruiting
Royal Infirmary of Edinburgh
Edinburgh, Scotland, EH16 4SA
- Recruiting
NIHR Leicester Biomedical Research Centre - Glenfield Hospital
Leicester, England, LE3 9QP
- Recruiting
St Bartholomew's Hospital - PPDS
London, Greater London, EC1A 7BE
- Recruiting
Royal Brompton Hospital
London, SW3 6NP
- Recruiting
Perth Royal Infirmary
Perth, Scotland, PH1 1NX
- Recruiting
Southampton General Hospital
Southampton, Hampshire, SO16 6YD
France6 sites, 6 recruiting
- Recruiting
CHU Amiens Picardie - Site Sud
Amiens, Somme, 80054
- Recruiting
AP-HP - Hopital Avicenne
Bobigny, Seine-Saint-Denis, 93000
- Recruiting
Hospices Civils de Lyon - Groupement Hospitalier Est
Bron, 69500
- Recruiting
AP-HM - Hôpital Nord
Marseille, Bouches-du-Rhône, 13915
- Recruiting
CHU de Nice-Hôpital Pasteur
Nice, Alpes-Maritimes, 6001
- Recruiting
CHU de Rennes - Hôpital Pontchaillou
Rennes, Ille-et-Vilaine, 35000
Taiwan6 sites, 6 recruiting
- Recruiting
Changhua Christian Hospital
Changhua, 50006
- Recruiting
Kaohsiung Medical University - Chung-Ho Memorial Hospital
Kaohsiung City, 80756
- Recruiting
Far Eastern Memorial Hospital
New Taipei City, 220
- Recruiting
Taichung Veterans General Hospital
Taichung, 407219
- Recruiting
National Taiwan University Hospital
Taipei, 106
- Recruiting
Taipei Veterans General Hospital
Taipei, 112201
Chile5 sites, 5 recruiting
- Recruiting
Centro de Investigacion Curicó
Curicó, Maule Region, 3341643
- Recruiting
CEC SpA
Ñuñoa, Santiago Metropolitan, 7750495
- Recruiting
Biocinetic Servicios Medicos Ltda
Santiago, Santiago Metropolitan, 8320000
- Recruiting
Centro de Investigacion de Enfermedades Respiratorias e Inmunologicas
Viña del Mar, Valparaiso, 2520000
- Recruiting
Centro de Investigaciones Clinicas Vina del Mar
Viña del Mar, Valparaiso, 2520000
Peru5 sites, 5 recruiting
- Recruiting
Hospital Chancay y Servicios Basicos de Salud
Chancay, Lima region, 15131
- Recruiting
Clinica Internacional - PPDS
Lima, Lima Province, 15001
- Recruiting
Clinica Ricardo Palma - PPDS
Lima, Lima Province, 15046
- Recruiting
Clinica Providencia - PPDS
San Miguel, Lima region, 15001
- Recruiting
Clinica San Pablo Surco
Surco, Lima region, 15555
New Zealand4 sites, 4 recruiting
- Recruiting
Canterbury Respiratory Research Group
Christchurch, Canterbury, 8001
- Recruiting
Greenlane Clinical Centre
Epsom, Auckland, 1051
- Recruiting
Health New Zealand - Te Whatu Ora - Waikato Hospital
Hamilton, Waikato Region, 3240
- Recruiting
Aotearoa Clinical Trials Trust - Middlemore Hospital - PPDS
Papatoetoe, Auckland, 2025
Poland4 sites, 4 recruiting
- Recruiting
Centrum Medycyny Oddechowej Mroz sp. j.
Bialystok, Podlaskie Voivodeship, 15-044
- Recruiting
SpiroClinic
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-079
- Recruiting
PULMAG s.c.
Sosnowiec, Silesian Voivodeship, 41-208
- Recruiting
Alergopneuma Centrum Medyczne - Swidnik
Świdnik, Lublin Voivodeship, 21-040
Serbia4 sites, 4 recruiting
- Recruiting
University Clinical Center of Serbia - Koste Todorovica - PPDS
Belgrade, 11000
- Recruiting
Institute of Pulmonary Diseases of Vojvodina
Kamenitz, Syrmia, 21204
- Recruiting
University Clinical Center Kragujevac
Kragujevac, 34000
- Recruiting
University Clinical Center Nis
Niš, 18 000
Spain4 sites, 4 recruiting
- Recruiting
Hospital Universitario Infanta Leonor
Madrid, 28031
- Recruiting
Hospital Universitario Virgen de la Victoria
Málaga, Malaga, 29010
- Recruiting
CHUS-Hospital Clinico Universitario de Santiago
Santiago de Compostela, A Coruña, 15706
- Recruiting
Hospital Clinico Universitario de Valencia
Valencia, Valencia, 46010
Belgium2 sites, 2 recruiting
- Recruiting
Cliniques Universitaires Saint-Luc - PPDS
Brussels, 1200
- Recruiting
CHU UCL Namur - Site Godinne
Yvoir, 5530
Denmark1 site, 1 recruiting
- Recruiting
Odense Universitetshospital
Odense C, Region Syddanmark, 5000
Germany1 site, 1 recruiting
- Recruiting
Universitätsklinikum Gießen und Marburg GmbH - Standort Gießen
Giessen, Hesse, 35392
Portugal1 site, 1 recruiting
- Recruiting
ULS de São José, EPE - Hospital de Santa Marta
Lisbon, 1169-024
About this study
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with or without background treatment.
Read the detailed description
This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and PK of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary Fibrosis with or without background treatment. The treatment period is 26 weeks and full study duration is up to 36 weeks including Screening and Follow-Up. Approximately 324 participants will be enrolled into one of three treatment arms, PIPE-791 Dose A, PIPE-791 Dose B, or placebo.
- Conditions
- Idiopathic Pulmonary Fibrosis
- Being tested
- PIPE-791 Dose A, PIPE-791 Dose B, Placebo
- Keywords
- Idiopathic Pulmonary Fibrosis, PIPE 791, Pulmonary Fibrosis, IPF, ILD, Interstitial lung disease
- Medical subject headings
- Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Lung Diseases, Interstitial
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PIPE-791 Dose ADrug
Also called PIPE-791
Participants will receive a daily oral dose of PIPE-791 in tablet form
PIPE-791 Dose BDrug
Also called PIPE-791
Participants will receive a daily oral dose of PIPE-791 in tablet form
PlaceboDrug
Participants will receive a daily oral dose of matching Placebo in tablet form
| Study group | Role | What they receive |
|---|---|---|
| PIPE-791 Dose A | Experimental | Not described Receives: Drug: PIPE-791 Dose A |
| PIPE-791 Dose B | Experimental | Not described Receives: Drug: PIPE-791 Dose B |
| Placebo | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Absolute change in forced vital capacity (FVC) (mL)
Measured: From baseline to Week 26
Secondary outcomes (7)
To investigate the safety and tolerability of PIPE-791 compared to placebo based on percentage of treatment-emergent adverse events (TEAE)
Measured: From baseline to Week 30
Relative change in FVC (mL)
Additional assessment of disease progression through lung function measurements
Measured: From baseline to Week 26
Proportion of participants with a ≥10% absolute decline in percent predicted FVC (ppFVC)
Measured: From baseline to Weeks 12 and Week 26
Time to first ≥10% absolute decline in ppFVC
Measured: From baseline to time of first ≥10% absolute decline, up to Week 26
Absolute change in ppFVC
Additional assessment of disease progression through lung function measurements
Measured: From baseline to Week 26
Relative change in ppFVC
Additional assessment of disease progression through lung function measurements
Measured: From baseline to Week 26
Change in quantitative CT-derived lung fibrosis burden on HRCT
Additional assessment of disease progression through imaging
Measured: From baseline to Week 26
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Dec 2025
- Study start8 Jan 2026
- Primary completionMay 2028 (estimated)
- Study completionJun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Idiopathic Pulmonary FibrosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 324 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Contineum Therapeutics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Mudiaga O Sowho, MD, MPH, Study director, Contineum Therapeutics
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07284459
- Sponsor's protocol ID
- CTX-791-201
- Status last verified
- Oct 2026
- First submitted
- 8 Dec 2025
- Last updated
- 5 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
- ClinicalTrials.gov ID
- NCT07284459
- Acronym / sponsor ID
- CTX-791-201
- Conditions
- Idiopathic Pulmonary Fibrosis
- Keywords
- Idiopathic Pulmonary Fibrosis, PIPE 791, Pulmonary Fibrosis, IPF, ILD, Interstitial lung disease
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 324 participants (estimated)
- Lead sponsor
- Contineum TherapeuticsIndustry (pharma, biotech, devices)
- Study start
- 8 Jan 2026 (actual)
- Primary completion
- May 2028 (estimated)
- Study completion
- Jun 2028 (estimated)
- First posted
- 16 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with or without background treatment.
Detailed description
This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and PK of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary Fibrosis with or without background treatment. The treatment period is 26 weeks and full study duration is up to 36 weeks including Screening and Follow-Up. Approximately 324 participants will be enrolled into one of three treatment arms, PIPE-791 Dose A, PIPE-791 Dose B, or placebo.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| PIPE-791 Dose A | Experimental | Drug: PIPE-791 Dose A |
| PIPE-791 Dose B | Experimental | Drug: PIPE-791 Dose B |
| Placebo | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Male or female ≥ 40 years of age at the time of Randomization.
- A diagnosis of IPF within 7 years prior to Screening, based on the 2022 ATS/ERS/JRS/ALAT practice guideline as confirmed by the Investigator, and a centrally read screening HRCT consistent with usual interstitial pneumonia (UIP) or probable UIP.
- Percent predicted (pp) FVC ≥ 40% on Screening spirometry.
- Participants may enter the study whether or not they are receiving background nintedanib or pirfenidone therapy approved for the treatment of IPF, but not both concurrently.
Key exclusion criteria (6 listed)
- Those with a history of interstitial lung disease (ILD) other than IPF are not eligible.
- Those with pulmonary arterial hypertension (PAH) requiring multi-drug therapy are not eligible.
- Those who have experienced an IPF exacerbation within 6 weeks of Screening, or during Screening, are not eligible.
- Those with an estimated glomerular filtration rate (eGFR) ≤ 30 ml/min/1.73 m2 (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) (Inker 2021) or who have Child-Pugh Class B or C hepatic impairment are not eligible.
- Female participants must not be of childbearing potential.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PIPE-791 Dose AAlso: PIPE-791Participants will receive a daily oral dose of PIPE-791 in tablet form | Drug | PIPE-791 Dose A |
| PIPE-791 Dose BAlso: PIPE-791Participants will receive a daily oral dose of PIPE-791 in tablet form | Drug | PIPE-791 Dose B |
| PlaceboParticipants will receive a daily oral dose of matching Placebo in tablet form | Drug | Placebo |
Primary outcome
Absolute change in forced vital capacity (FVC) (mL)
Time frame: From baseline to Week 26
7 secondary outcomes
To investigate the safety and tolerability of PIPE-791 compared to placebo based on percentage of treatment-emergent adverse events (TEAE)
Time frame: From baseline to Week 30
Relative change in FVC (mL)
Time frame: From baseline to Week 26
Proportion of participants with a ≥10% absolute decline in percent predicted FVC (ppFVC)
Time frame: From baseline to Weeks 12 and Week 26
Time to first ≥10% absolute decline in ppFVC
Time frame: From baseline to time of first ≥10% absolute decline, up to Week 26
Absolute change in ppFVC
Time frame: From baseline to Week 26
Relative change in ppFVC
Time frame: From baseline to Week 26
Change in quantitative CT-derived lung fibrosis burden on HRCT
Time frame: From baseline to Week 26
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Idiopathic Pulmonary Fibrosis
RecruitingPhase 2
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
RecruitingObservational study
Real-world Study of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
RecruitingPhase 2
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)
Not yet recruitingPhase 2
A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)
Active, not recruitingPhase 2
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
Idiopathic Pulmonary Fibrosis (IPF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mudiaga O Sowho, MD, MPH study director
Contineum Therapeutics
108 sites in 19 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing PIPE-791 Dose A and PIPE-791 Dose B in people with Idiopathic Pulmonary Fibrosis, run by Contineum Therapeutics at 108 sites in 19 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 108 sites in Argentina, Israel, Australia, South Korea, Canada and 14 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nikki Nepomuceno (858-333-5280, nnepomuceno@contineum-tx.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Absolute change in forced vital capacity (FVC) (mL) (time frame: From baseline to Week 26). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.